Company News

Proseek Bio is delighted to announce that Kirsty Garrett has joined us as Board Chair. Kirsty is an accomplished and forward-thinking leader with more than 35 years of experience, much of it in the high-growth technology sector. She joins us at an important moment, as we continue building the foundations to bring new blood-based diagnostic tools from the lab into clinical practice. Building and scaling in digital health Kirsty brings direct operating experience from the CEO s

We're delighted to announce that Dr. David Herold, MD, PhD, has joined Proseek Bio as our first Clinical Advisor. It's a milestone moment for us. As we continue developing our blood test to help clinicians better assess suspicious ovarian masses, and work toward closing the diagnostic gap in women's health, having someone of David's calibre and experience guiding us is invaluable. About Dr. David Herold David brings decades of expertise in clinical pathology and mass spectrom

Proseek Bio is pleased to announce the appointment of Peter Bradley as Non-Executive Director. Peter brings extensive leadership experience across the biotechnology, medical technology, and life sciences sectors, with a strong track record of supporting innovation, commercial growth, and strategic development. His appointment strengthens Proseek Bio's Board as the company continues to advance diagnostics designed to improve earlier detection and clinical decision-making in ov

Proseek Bio is pleased to announce that our research has been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, one of the world's leading forums for oncology research, clinical practice, and innovation. The accepted abstract, published in the Journal of Clinical Oncology, reports findings from an international collaboration between Australia and Malaysia. The study highlights the successful completion of an inter-laboratory de

We’re proud to announce that Proseek Bio has been selected to join the 2026 BioTools Innovator cohort; a globally competitive accelerator program spotlighting the most promising companies advancing life science tools and diagnostics. Chosen from a pool of nearly 550 applicants, Proseek Bio is one of just 30 companies selected, placing it among the top tier of emerging innovators in the field. This milestone reflects both the strength of our platform and the growing recognitio

Proseek Bio has been selected for the UNSW Global Landing Pads program, supporting our upcoming expansion into the United States.

Proseek Bio has been selected to advance to Phase 2 of the BioTools Innovator 2026 program.

Proseek Bio has closed an oversubscribed A$1.5M seed round to advance the development of OC-Triage, our blood-based test for ovarian cancer.